๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

26 recruiting trials

for Ovarian Clear Cell Carcinoma

A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) NCT06023862Phase 227 sites๐Ÿ“ Clayton๐Ÿ“ Waratah๐Ÿ“ Melbourne Yonsei University ยท Tests: Dostarlimab, Bevacizumab, Doxorubicin, Gemcitabine, Paclitaxel 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors NCT07557225NA1 site๐Ÿ“ Beijing Peking University First Hospital ยท Tests: 18F-T2 PET/CT IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors NCT05039801Phase 11 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Bevacizumab, Glutaminase-1 Inhibitor IACS-6274, Paclitaxel, Capivasertib Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma NCT05112601Phase 2138 sites๐Ÿ“ Birmingham๐Ÿ“ Athens๐Ÿ“ Augusta National Cancer Institute (NCI) ยท Tests: Biospecimen Collection, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab Study of NTB-928 in R/R OC NCT07690189Phase 14 sites๐Ÿ“ Birmingham๐Ÿ“ Omaha๐Ÿ“ Lake Success TeneoSeven, Inc. ยท Tests: NTB-928 Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100 NCT06065462Phase 1, Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Dostarlimab, LB-100 Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors. NCT07303387Phase 24 sites๐Ÿ“ Villejuif๐Ÿ“ Bordeaux๐Ÿ“ Lyon Gustave Roussy, Cancer Campus, Grand Paris ยท Tests: Valemetostat Tosylate A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy NCT05460000Phase 250 sites๐Ÿ“ Innsbruck๐Ÿ“ Brussels๐Ÿ“ Ghent North Eastern German Society of Gynaecological Oncology ยท Tests: 3 cycles chemotherapy instead of 6 cycles chemotherapy, 6 cycles chemotherapy Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring NCT05500391Phase 23 sites๐Ÿ“ Amiens๐Ÿ“ Caen๐Ÿ“ Lille Centre Oscar Lambret ยท Tests: Oncological Follow-up APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion NCT04919629Phase 21 site๐Ÿ“ Buffalo Roswell Park Cancer Institute ยท Tests: Bevacizumab, Biopsy, Biospecimen Collection, Pegcetacoplan, Pembrolizumab Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer NCT06321484Phase 12 sites๐Ÿ“ Boston๐Ÿ“ Boston Dana-Farber Cancer Institute ยท Tests: Cytokine-Induced Memory-like Natural Killer Cells, Interleukin 2 A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas NCT04104776Phase 1, Phase 280 sites๐Ÿ“ Tampa๐Ÿ“ Atlanta๐Ÿ“ Chicago Novartis Pharmaceuticals ยท Tests: Tulmimetostat, Enzalutamide A Study of MGC026 in Participants With Advanced Solid Tumors NCT06242470Phase 112 sites๐Ÿ“ Los Angeles๐Ÿ“ Grand Rapids๐Ÿ“ Lake Success MacroGenics ยท Tests: MGC026 Dose Escalation, MGC026 Dose for Expansion Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin NCT06677190Phase 22 sites๐Ÿ“ Boston๐Ÿ“ Boston Dana-Farber Cancer Institute ยท Tests: Belzutifan A Study of Lorigerlimab in Participants With Advanced Solid Tumors NCT06730347Phase 216 sites๐Ÿ“ Los Angeles๐Ÿ“ New Orleans๐Ÿ“ Grand Rapids MacroGenics ยท Tests: Lorigerlimab A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer NCT06380816Phase 1, Phase 24 sites๐Ÿ“ London๐Ÿ“ Manchester๐Ÿ“ Newcastle upon Tyne Cancer Research UK ยท Tests: UCB4594 Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial NCT04575935Phase 319 sites๐Ÿ“ Miami๐Ÿ“ Weston๐Ÿ“ Boston M.D. Anderson Cancer Center ยท Tests: Chemotherapy, Laparotomy, Minimally Invasive Surgery, Quality-of-Life Assessment, Questionnaire Administration Folate Receptor Alpha Dendritic Cells (FRฮฑDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial NCT06639074Phase 23 sites๐Ÿ“ Scottsdale๐Ÿ“ Jacksonville๐Ÿ“ Rochester Mayo Clinic ยท Tests: Biopsy, Biospecimen Collection, Computed Tomography, Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorโ€ฆ A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors NCT06270706Phase 122 sites๐Ÿ“ New Haven๐Ÿ“ Atlanta๐Ÿ“ Grand Rapids Pliant Therapeutics, Inc. ยท Tests: PLN-101095, PLN-101095, PLN-101095, PLN-101095, PLN-101095 Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer NCT07718854Phase 21 site๐Ÿ“ Boston Tufts Medical Center ยท Tests: Sacituzumab tirumotecan, Pembrolizumab Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors NCT07517198Phase 13 sites๐Ÿ“ Los Angeles๐Ÿ“ Fort Worth๐Ÿ“ West Valley City Exscientia AI Ltd., a wholly owned subsidiary of Recursion โ€ฆ ยท Tests: EXS74539 INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma NCT07002346Phase 31 site๐Ÿ“ Wuhan Tongji Hospital ยท Tests: QL1706 (bispecific antibody targeting PD-1 and CTLA-4), Bevacizumab, carboplatin, Paclitaxel A Beta-only IL-2 ImmunoTherapY Study NCT05086692Phase 1, Phase 228 sites๐Ÿ“ San Diego๐Ÿ“ San Francisco๐Ÿ“ Santa Monica Medicenna Therapeutics, Inc. ยท Tests: MDNA11, Pembrolizumab (KEYTRUDAยฎ) Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer NCT05231122Phase 22 sites๐Ÿ“ Buffalo๐Ÿ“ Houston Roswell Park Cancer Institute ยท Tests: Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Bevacizumab, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Aโ€ฆ Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer NCT05950464Phase 114 sites๐Ÿ“ Augusta๐Ÿ“ Chicago๐Ÿ“ Iowa City National Cancer Institute (NCI) ยท Tests: BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Iโ€ฆ Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) NCT05281471Phase 333 sites๐Ÿ“ Mobile๐Ÿ“ Tucson๐Ÿ“ Duarte Genelux Corporation ยท Tests: olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Phโ€ฆ
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy